NevoLine™ – The Next Evolution of Viral Production

NevoLine Biomanufacturing platform for viral production at affordable costs and low footprint- Univercells biotech Belgium - BMGF

Brussels, 21 February 2019

Increase availability & affordability of vaccines

The world is facing an under-supply of some key vaccines due to poor synergies between growing market demands and aging production models.

In this light, Univercells developed a vaccine manufacturing platform aiming at increasing availability and affordability of vaccines – NevoLine™ system.

NevoLine – intensified & automated viral production system

Based on a novel process architecture, Univercells designed the automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint. Through intensification and chaining of unit steps into a continuous process, users achieve high yields with less time and money invested.

The system was initially developed as part of a $12M Grand Challenges grant awarded by the Bill & Melinda Gates Foundation to deliver affordable inactivated polio vaccine (sIPV).




Cost-effective Production Automated Operations Rapid deployment
Reduced footprint & simplified infrastructure Virus Containment fast implementation in new or existing facility
Low capital investment Environment and operators safety Reduced time-to-market
Low operational expenditures Adaptable to epidemic preparedness approches


  • Brochure
    | Nevoline

    The NevoLine™ platform: the next evolution of viral production

    The NevoLine platform provides intensified & automated viral production in 10 m², drastically reducing facility footprint & investment requirements.

  • Want to know more
    about our NevoLine system?

    Contact us